HIV/AIDS

A herpes medication can reduce HIV activity, according to researchers from Case Western Reserve.

Study results show transgender women living with HIV are less likely to adhere to anti-HIV medication regimens and achieve viral suppression rates, and are more likely than non-transgender men to be deprived of basic needs.

Researchers at Rockefeller University in New York City suggest that a member of a new generation of broadly neutralizing antibodies to HIV appears to reduce the viral load of patients with the infection and significantly reduce viremia through 28 days.

The first large-scale clinical trial of its kind has confirmed big news when it comes to treatment for patients with the human immunodeficiency virus (HIV).

Sitagliptin appears to have beneficial systemic and adipose anti-inflammatory effects in combination antiretroviral therapy-treated HIV-positive adults with impaired glucose tolerance. The drug may prevent cardiovascular problems by reducing inflammation linked to heart disease and stroke in this patient population.

Chronic kidney disease developed in association with exposure to antiretrovirals in people with initially normal levels of estimated glomerular filtration rate (eGFR) was not limited to increased incidence immediately after starting therapy but in fact increased over time and exposure.

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.

Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects

Study results show that a regimen of three antiretroviral drugs taken during pregnancy significantly reduces the rate of mother-to-child HIV transmission.

The most common causes of lipodystrophy are insulin injection, antiretroviral drugs, and hereditary disorders. Some patients with insulin-related lipodystrophy also develop metabolic dysfunction, including insulin resistance, elevated free fatty acids level, abnormal adipocytokine secretion, and ectopic fat deposition.

U.S. physicians may not be following the latest guidelines on HIV care, a US Centers for Disease Control and Prevention (CDC)'s Morbidity and Mortality Weekly Report concludes.

A national clinical trial has found non-efavirenz antiretroviral therapy effective as a first-line treatment, which is good news for patients with HIV who are ineligible to use the common drug.

Understanding the current guidelines for hepatitis C (HCV) treatment and the role of direct-acting antiviral (DAA) agents is a priority for healthcare professionals.